Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

  1. OncologyPRO
  2. Meeting Resources
  3. ESMO 2018 Congress

Immune therapies going adjuvant: Benefits versus risks

Immunotherapy checkpoints: What to tell your patients - How long should we treat patients?

Date

19 Oct 2018

Session

Immune therapies going adjuvant: Benefits versus risks

Topics

Immunotherapy;  Patient Education and Advocacy

Tumour Site

Presenters

John Haanen

Authors

J.B.A.G. Haanen

Author affiliations

  • Medical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Login

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.